

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 4. (Canceled)

5. (Currently Amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) a mature form of the amino acid sequence SEQ ID NO:14; and
- (b) ~~a variant of a mature form of the amino acid sequence SEQ ID NO:14, wherein one amino acid residue in said variant differs from the amino acid sequence of said mature form;~~
- (c) ~~(b) SEQ ID NO:14;~~
- (d) ~~a variant of the amino acid sequence of SEQ ID NO:14, wherein one amino acid residue in said variant differs from the amino acid sequence of SEQ ID NO:14;~~
~~and~~
- (e) ~~a fragment of SEQ ID NO:14 selected from the group consisting of residues: 1-400, 450-520, 750-850, 1100-1200, 1250-1400, 1490-1750, 1760-2300, 2400-2600, and 2650-2725.~~

6. - 8. (Canceled)

9. (Currently Amended) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) SEQ ID NO:13; and
- (b) ~~a nucleotide sequence differing by one nucleotide from a nucleotide sequence of SEQ ID NO:13;~~
- (c) ~~(b) the complement of (a) or (b) SEQ ID NO:13.~~

10. - 11. (Canceled)

12. (Original) A vector comprising the nucleic acid molecule of claim 5.

13. (Original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.

14. (Original) A cell comprising the vector of claim 12.

15. - 38. (Canceled)

39. (Previously Presented) A composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.

40. - 41. (Canceled)

42. (Previously Presented) A kit comprising in one or more containers, the composition of claim 39.

43. - 49. (Canceled)

50. (Previously Presented) An isolated nucleic acid molecule comprising the complement of the nucleic acid molecule of claim 5.

51. (Currently Amended) The A variant of the isolated nucleic acid molecule of claim 5 wherein the amino acid residue at position 28 of SEQ ID NO: 14 is Asp or Gly.

52. (Currently Amended) The A variant of the isolated nucleic acid molecule of claim 5 wherein the amino acid residue at position 64 of SEQ ID NO: 14 is Val or Ala.

53. (Currently Amended) The A variant of the isolated nucleic acid molecule of claim 5 wherein the amino acid residue at position 76 of SEQ ID NO: 14 is Ala or Thr.
54. (Previously Presented) A vector comprising the nucleic acid molecule of claim 9.
55. (Currently Amended) The vector of claim 53 54, further comprising a promoter operably-linked to said nucleic acid molecule.
56. (Previously Presented) A cell comprising the vector of claim 54.
57. (Currently Amended) The A variant of the isolated nucleic acid molecule of claim 9 wherein the nucleotide residue at position 117 of SEQ ID NO: 13 is A or G.
58. (Currently Amended) The A variant of the isolated nucleic acid molecule of claim 9 wherein the nucleotide residue at position 225 of SEQ ID NO: 13 is T or C.
59. (Currently Amended) The A variant of the isolated nucleic acid molecule of claim 9 wherein the nucleotide residue at position 260 of SEQ ID NO: 13 is G or A.
60. (New) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising residues 371-830 of SEQ ID NO:14.
61. (New) A variant of the isolated nucleic acid molecule of claim 5, wherein the variant comprises a nucleic acid sequence encoding an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO:14.